← All trials
NCT04901455
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- May 25, 2021
- Last posted
- Sep 8, 2021
- Enrollment
- 40
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of North Carolina at Chapel HillLead sponsor
- University of North Carolina at Chapel HillOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.